Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)
Cycloserine
Neon Healthcare Ltd
J04AB01
Cycloserine
250mg
Oral capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 05010900; GTIN: 5033003002257
OBJECT 1 CYCLOSERINE Summary of Product Characteristics Updated 07-Feb-2018 | King Pharmaceuticals Ltd 1. Name of the medicinal product CYCLOSERINE 2. Qualitative and quantitative composition Each capsule contains as active ingredient 250 mg of cycloserine. 3. Pharmaceutical form Capsule, hard. 4. Clinical particulars 4.1 Therapeutic indications _Actions:_ Cycloserine inhibits cell wall synthesis in susceptible strains of Gram-positive and Gram- negative bacteria and in Mycobacterium tuberculosis. _Indications:_ Cycloserine is indicated in the treatment of active pulmonary and extra-pulmonary tuberculosis (including renal disease) when the organisms are susceptible to this drug and after failure of adequate treatment with the primary medications (streptomycin, isoniazid, rifampicin and ethambutol). Like all anti-tuberculous drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of Gram-positive and Gram-negative bacteria, especially Klebsiella/Enterobacter species and Escherichia coli. It is generally no more and may be less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of cycloserine in these infections should be considered only when the more conventional therapy has failed and when the organism has been demonstrated to be sensitive to the drug. 4.2 Posology and method of administration Posology _Adults: _the usual dosage is 500 mg to 1 g daily in divided doses, monitored by blood level determinations. The initial adult dosage most frequently given is 250 mg twice daily at 12-hour intervals for the first two weeks. A daily dosage of 1g should not be exceeded. _The elderly: _as for adults but reduce dosage if renal function is impaired. _Paediatric population _ The usual starting dose is 10 mg/ kg/ day, then adjusted according to blood levels o Izlasiet visu dokumentu